A study linking popular weight loss drug to suicide risk again raises long-standing safety questions

August 22, 2024August 22, 2024 Tina Marie (Ms. Cat)

Editor’s Note: If you or someone you know is struggling with suicidal thoughts or mental health matters, please call the 988 Suicide & Crisis Lifeline by dialing 988 to connect with a trained counselor, or visit the 988 Lifeline website.

People taking semaglutide, the popular medication for diabetes and weight loss, are more likely to report having thoughts of suicide compared with those taking other drugs, according to a new study of an international drug safety database. But the finding is the latest see-saw of scientific evidence on the risk of depression and suicide tied to the popular medications — and critics say evidence that the drugs cause problems with mood is limited.

A study linking popular weight loss drug to suicide risk again raises long-standing safety questions

I am an epidemiologist, currently funded by GlaxoSmithKline. I initially studied physiology at BSc and PhD level in Manchester. Since then, I spent several years at the UK Medicines & Healthcare Products Regulatory Agency and in the pharmaceutical industry investigating adverse effects of drugs – both in clinical trials and post-marketing. I completed the MSc in epidemiology at LSHTM in 2005.

Previously:

Medicare to cover obesity drugs, but not for weight loss

Wegovy, Rybelsus, and Ozempic, are the different brand names for Semaglutide. They have a black box warning for Medullary thyroid cancer.* 🤦🏼‍♀️

Related:

Wegovy side effects: What you should know

*Obesity and Cancer

Everything We Learned From Oprah’s Weight Loss Special

Mounjaro:

Using Mounjaro may increase your risk of developing thyroid cancer.

Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here’s What’s Next

January 6, 2024September 25, 2024 Tina Marie (Ms. Cat)

Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here’s What’s Next

Yet one glaring problem remains. Despite promising clinical results, no one knows exactly how psychedelic drugs work in the brain. Examining their actions on brain cells isn’t just an academic curiosity. It could give rise to variants that maintain antidepressant properties without the high. And because hallucinogens substantially alter our perception [management?!] of the world, they could be powerful tools for investigating the neurobiology behind consciousness.

…

This year, scientists found another common theme—psychedelics seem to “reset” the brain to a more youthful state, at least in mice. Like humans, mice have an adolescent critical period, during which their brains are highly malleable and can easily rewire neural circuits, but the window closes after adulthood.

…

An earlier study showed that MDMA reopens the critical window in adult mice, so that they change their “personality.” Mice raised alone are often introverted and prefer to keep to themselves in adulthood. A dose of MDMA increased their willingness to snuggle with other mice—essentially, they learned to associate socializing with happiness, concluded the study.

It’s not that surprising. MDMA is well-known to promote empathy and bonding. The new study, by the same team, extended their early results to four psychedelics that don’t trigger fuzzy feelings—LSD, ketamine, psilocybin, and ibogaine. Similar to MDMA, adult mice raised alone changed their usual preference for solitude when treated with any of the drugs. Because habits are hard to change in adulthood—for mice and men—the drugs may have reopened the critical period, allowing the brain to more easily rewire neural connections based on new experiences.

…

These are just early results. But psychedelic research is gaining a new ally—artificial intelligence. Algorithms that predict protein structure, combined with rational drug design, could generate psychedelics that retain their psychiatric benefits without the high.